Key Highlights

  • Mirum Pharmaceuticals grew second-quarter net product sales 38% to $176.2 million, led by LIVMARLI's $128.7 million contribution.
  • TG Therapeutics' BRIUMVI US net product Revenue reached $227.7 million, up roughly 64% from a year earlier.
  • IDEAYA Biosciences' registrational OptimUM-02 trial met its primary endpoint for its lead eye-cancer program.
  • Tandem Diabetes Care's second-quarter total sales rose 6% to $254.6 million, split between US and international markets.

Health care has long been one of the busiest neighbourhoods of the Nasdaq Composite, and September 2026 finds it split between companies already generating real revenue and those still spending toward their first approvals. The five tickers here capture that spread. Tandem Diabetes Care (NASDAQ:TNDM), Tactile Systems Technology (NASDAQ:TCMD), Mirum Pharmaceuticals (NASDAQ:MIRM) and TG Therapeutics (NASDAQ:TGTX) are all selling products today; IDEAYA Biosciences (NASDAQ:IDYA) is racing a lead cancer candidate toward the regulatory finish line.

Numbers here trace to primary releases and company investor materials. Nothing about future prices, ratings or trial outcomes is predicted with certainty, where the text looks forward, it is labelled as such and hedged.

The sector backdrop heading into autumn 2026

Two forces frame this group. The first is the durable Demand story behind chronic-disease and rare-disease treatment: diabetes-technology adoption, lymphedema and airway-clearance therapy, multiple-sclerosis immunology, and orphan drugs that command concentrated patient populations. The second is the market's continued preference, after several tighter-funding years, for companies that can point to growing sales or a well-capitalised Balance Sheet rather than open-ended cash burn.

That backdrop rewards different things in different names. For the device makers, the questions are gross margin, new-product cadence and payer access. For the commercial drugmakers, it is the slope of the revenue ramp and how much of it drops to the bottom line. For a clinical-stage developer, it is catalyst timing and runway. The five companies below sit at distinct points on that map, which is precisely why they are worth reading together.

Tandem Diabetes Care (NASDAQ:TNDM) leans on new products to reaccelerate

Tandem Diabetes Care (NASDAQ:TNDM) is a San Diego maker of insulin pumps and automated insulin-delivery software. For the second quarter of 2026, the company reported total sales of $254.6 million, up 6% year over year, with U.S. sales of $179.3 million and international sales of $75.3 million. Its GAAP net loss narrowed to $21.2 million from $52.4 million a year earlier, and management reaffirmed full-year 2026 sales guidance of roughly $1.065 billion to $1.085 billion.

The product news arguably matters as much as the numbers. Tandem said its Control-IQ+ algorithm received FDA clearance for use during pregnancy in people with type 1 diabetes, and it filed a 510(k) submission with the FDA for tubeless capability on the Tandem Mobi pump. It also began Mobi's international rollout and added compatibility with newer Dexcom and Abbott sensors.

A 6% Top Line points to a mature, competitive pump market where Tandem must win on features. If the tubeless submission clears and Mobi's global launch broadens, Tandem's growth mix could shift, but clearance timing and payer coverage remain the swing factors, and neither is guaranteed.

IDEAYA Biosciences (NASDAQ:IDYA) approaches a defining regulatory moment

IDEAYA Biosciences (NASDAQ:IDYA) is a clinical-stage precision-oncology company. Its lead program, darovasertib, partnered with Servier, is aimed at metastatic uveal melanoma, a rare and hard-to-treat eye cancer. IDEAYA reported that the registrational OptimUM-02 trial met its primary endpoint, with the darovasertib combination showing a statistically significant median progression-free survival improvement of 6.9 months versus 3.1 months in the control arm among HLA-A\*02:01-negative patients. The company said an NDA filing is underway under the FDA's real-time oncology review program, with completion expected in the second half of 2026.

IDEAYA held approximately $1.24 billion in cash, cash equivalents and marketable securities as of 30 June 2026, and guided to a runway extending into 2030. Q2 net loss was $112.5 million on R&D expense of $108.7 million.

The balance sheet is the story's ballast, buying time across a deep pipeline that includes the DLL3 ADC IDE849 and MTAP-pathway programs. A darovasertib approval would transform IDEAYA from developer to commercial company, but regulators, not trial data alone, determine that outcome, and timing can slip.

Tactile Systems Technology (NASDAQ:TCMD) grinds out chronic-care growth

Tactile Systems Technology (NASDAQ:TCMD), which markets under the Tactile Medical name, makes at-home devices for chronic conditions. In the second quarter of 2026, it reported total revenue of $85.7 million, up 9% year over year. Lymphedema products, led by the Flexitouch platform, contributed $73.6 million, up 12%, while airway-clearance products fell 7% to $12.1 million. GAAP Net Income was $7.8 million, or $0.34 per diluted share, and adjusted EBITDA rose to $11.4 million.

Management updated full-year 2026 revenue guidance to $360 million to $366 million, implying roughly 9% to 11% growth, and kept adjusted EBITDA guidance at $49 million to $51 million. The company launched a next-generation AffloVest system and signed a U.S. distribution agreement with ElastiMed for MyoSleeve devices serving VA and DoD populations.

Tactile is the quiet profitability story in this group, modest growth, but positive Earnings and a widening margin. The lymphedema Franchise looks like the reliable engine; the airway-clearance line's return to growth after its new-product launch is the open question worth tracking through the back half of the year.

Mirum Pharmaceuticals (NASDAQ:MIRM) scales its rare-disease franchise

Mirum Pharmaceuticals (NASDAQ:MIRM) is a rare-disease drugmaker whose commercial base spans cholestatic liver conditions and bile-acid disorders. Second-quarter 2026 net product sales reached $176.2 million, up 38% year over year, with LIVMARLI contributing $128.7 million (up 46%) and the bile-acid medicines portfolio adding $47.5 million (up 20%). Mirum raised full-year 2026 net product sales guidance to $680 million to $700 million and reported roughly $561.3 million in cash and investments at 30 June.

The quarter also carried a large GAAP net loss of $67.2 million, and the six-month loss ballooned to $857.4 million because of a non-recurring $742.7 million acquired in-process R&D charge tied to licensing zilurgisertib. On the pipeline, Mirum cited a September 2026 PDUFA target for zilurgisertib in a rare bone condition and progress for volixibat, which holds FDA Breakthrough Therapy and Orphan Drug designations in one cholestatic indication.

Strip out the one-time charge and the commercial engine is compounding quickly. Near-term catalysts, a regulatory decision and readouts, could reshape the pipeline narrative, though outcomes and exact timing remain outside the company's control.

TG Therapeutics (NASDAQ:TGTX) rides a maturing MS launch

TG Therapeutics (NASDAQ:TGTX) is built around BRIUMVI, its anti-CD20 therapy for relapsing forms of multiple sclerosis. For the second quarter of 2026, TG reported BRIUMVI U.S. net product revenue of $227.7 million and total revenue of $240.3 million, with BRIUMVI U.S. sales up roughly 64% versus the year-ago period. Net income was $7.8 million, or $0.05 per diluted share, down from $28.2 million and $0.17 a year earlier. The company raised its 2026 targets to about $950 million in total revenue and $890 million to $905 million in BRIUMVI U.S. net product revenue.

TG reported positive Phase 3 ENHANCE results supporting a simplified single-infusion regimen and said a subcutaneous BRIUMVI showed greater than 60% mean bioavailability relative to the IV form, with pivotal data expected around year-end 2026 or early 2027.

Rising revenue alongside a shrinking Bottom Line signals reinvestment in commercial reach and pipeline, a common trade-off at this stage. A subcutaneous option and new-indication studies could extend the franchise, but each depends on trials and regulators still ahead.

What investors should watch

The near-term calendars diverge sharply. For IDEAYA, the darovasertib NDA completion and ESMO presentations in October are the events to follow; for Mirum, a late-September regulatory decision and pipeline readouts loom. Tandem's FDA review of tubeless Mobi and the pace of its international rollout are the device-side catalysts, while TG Therapeutics' subcutaneous BRIUMVI data land around the turn of the year.

Cross-cutting risks apply. Payer coverage and pricing pressure touch every name; the drugmakers face binary regulatory and clinical outcomes; the device makers must keep launching to hold their growth rates. Balance-sheet strength, abundant at IDEAYA and TG, solid at Mirum, and paired with profitability at Tactile, will shape how much each can absorb a setback. None of these outcomes is assured, and readers should treat every forward-looking item here as a possibility, not a promise.

Commercial Products Next to a Pivotal Trial

Measured against each other, these five Nasdaq-listed companies are a useful cross-section of health technology in September 2026: a diabetes-device maker reaccelerating on new products, a well-funded oncology developer at a regulatory inflection, a steadily profitable chronic-care device firm, and two commercial drugmakers scaling rare-disease and MS franchises. The reported facts show real revenue growth across the commercial names and a landmark trial result at IDEAYA. What happens next, approvals, launches and pipeline reads, is genuinely uncertain. The disciplined approach is to weigh the disclosed numbers, respect the catalysts, and size the risks accordingly.